Loading
Life sciences · Journal article
BMC Medical Imaging · October 12, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Abstract Background Accurate preoperative assessment of HER2 status is critical for guiding targeted therapy, but conventional biopsy-based methods are invasive and limited by tumor heterogeneity. Mammography is a widely accessible and cost-effective imaging modality routinely performed in the preoperative setting. This study aimed to develop and validate a mammography-based deep learning radiomics model for noninvasive prediction of HER2 expression status in breast cancer. Methods A total of 546 breast cancer patients from two centers were retrospectively enrolled: 420 from Center 1 (294 in the training cohort and 126 in the internal validation cohort) and 126 from Center 2 as the external validation cohort. Two classification tasks were defined: Task 1 distinguished HER2-positive from HER2-negative breast cancer, and Task 2 distinguished HER2-low from HER2-zero breast cancer. Radiomic features were extracted using the Visformer architecture. A weighted voting ensemble method was then employed to construct the prediction model, with weights optimized solely within the training cohort using cross-validated AUC. Model performance for both tasks was evaluated using receiver operating characteristic (ROC) curves. Results For Task 1 (HER2-positive vs. HER2-negative), the radiomics model achieved AUCs of 0.836, 0.763, and 0.714 in the training, internal validation, and external validation cohorts, respectively. For Task 2 (HER2-low vs. HER2-zero), the corresponding AUCs were 0.890, 0.785, and 0.713. Clinicopathological analysis revealed that histological grade (OR = 2.28), Ki-67 index (OR = 4.71), and BI-RADS category (OR = 2.49) were independent predictors of HER2-positive status, while PR status (OR = 4.48), BI-RADS category (OR = 1.75), and breast density (OR = 0.32) were independent predictors of HER2-low status (all P < 0.05). Conclusion The mammography-based deep learning radiomics model demonstrated meaningful discriminative ability for predicting HER2 expression status in breast cancer and may serve as a potential noninvasive adjunct for preoperative HER2 assessment, warranting further prospective validation. Clinical trial number Not applicable.